Drug shortages homepage
Welcome to Drug Shortages Canada, the website for reporting drug shortages and discontinuations in Canada. The Food and Drug Regulations require drug sellers to report when they are not able to meet demand for a product or when they stop selling a product. Information about the website and the regulations can be found on the About & Resources Page.
A shortage means, in respect of a drug, a situation in which the manufacturer to whom a document was issued under subsection C.01.014.2(1) that sets out the drug identification number assigned for the drug is unable to meet the demand for the drug.
A discontinuation means, in respect of a drug, a situation in which the manufacturer to whom a document was issued under subsection C.01.014.2(1) that sets out the drug identification number assigned for the drug, permanently ceases the sale of the drug.
Tier 3 drug shortages are those that have the greatest potential impact on Canada's drug supply and health care system. Impact is based on low availability of alternative supplies, ingredients or therapies. The Tier Assignment Committee (TAC), composed of federal and provincial/territorial governments, healthcare professionals, and industry stakeholders, makes recommendations on the tier assignment of drug shortages. The TAC assessment includes:
- a review of the information gathered on the shortage issue, and
- a thorough discussion on its potential impact and next steps.
Below are the newest and most recently updated Shortage and Discontinuation reports. Alternatively, please visit the Tier 3 page to see current Tier 3 Drug Shortages and associated shortage or discontinuation reports.

LEGEND
!!T3 denotes an actual Tier 3 shortage/discontinuation
!T3 denotes an anticipated Tier 3 shortage/discontinuation
Shortage Reports
Brand name | Company Name | Status | Strength | Update | Date Updated | View Report |
---|---|---|---|---|---|---|
GD-DICLOFENAC/MISOPROSTOL 50 | GENMED A DIVISION OF PFIZER CANADA ULC | Actual shortage | 200MCG 50MG | Updated Report | 2023-01-30 | 180226 |
IDARUBICIN | PFIZER CANADA ULC | Anticipated shortage | 1MG | Updated Report | 2023-01-30 | 176929 |
YAZ PLUS | BAYER INC | Actual shortage | 0.451MG 0.451MG 0.02MG 3.00MG | Updated Report | 2023-01-30 | 172253 |
GENTAMICIN(E) | BAXTER CORPORATION | Actual shortage | 1.6MG | Updated Report | 2023-01-30 | 179918 |
JANUVIA | MERCK CANADA INC | Anticipated shortage | 100MG | Updated Report | 2023-01-30 | 182687 |
APO-VALPROIC ACID ORAL SOLUTION | APOTEX INC | Anticipated shortage | 250MG | Updated Report | 2023-01-30 | 182684 |
0.9% SODIUM CHLORIDE IRRIGATION, USP | BAXTER CORPORATION | Actual shortage | 900MG | Updated Report | 2023-01-30 | 181393 |
SORBITOL MANNITOL IRRIGATION | ICU MEDICAL CANADA INC | Actual shortage | 5.4MG 27MG | Updated Report | 2023-01-30 | 180329 |
SODIUM CHLORIDE INJECTION USP | ICU MEDICAL CANADA INC | Anticipated shortage | 9MG | New Report | 2023-01-30 | 182677 |
SODIUM CHLORIDE INJECTION USP | ICU MEDICAL CANADA INC | Anticipated shortage | 9MG | New Report | 2023-01-30 | 182674 |
Discontinuation Reports
Brand name | Company Name | Status | Strength | Update | Date Updated | View Report |
---|---|---|---|---|---|---|
RUZURGI | MEDUNIK CANADA | Reversed | 10MG | Updated Report | 2023-01-27 | 156611 |
FORADIL DRY POWDER CAPSULES FOR INHALATION | NOVARTIS PHARMACEUTICALS CANADA INC | Discontinued | 12MCG | Updated Report | 2023-01-25 | 172087 |
ONIVYDE | SERVIER CANADA INC | Reversed | 4.3MG | Updated Report | 2023-01-25 | 164803 |
IBAVYR | PENDOPHARM DIVISION OF PHARMASCIENCE INC | Discontinued | 200MG | Updated Report | 2023-01-20 | 182060 |
IBAVYR | PENDOPHARM DIVISION OF PHARMASCIENCE INC | Discontinued | 400MG | Updated Report | 2023-01-20 | 182029 |
GALLIUM | LANTHEUS MI CANADA INC | Discontinued | 74MBq | Updated Report | 2023-01-20 | 161428 |
BETOPTIC S | NOVARTIS PHARMACEUTICALS CANADA INC | Discontinued | 0.25% | Updated Report | 2023-01-19 | 170389 |
GLUCAGON | ELI LILLY CANADA INC | To be discontinued | 1MG | Updated Report | 2023-01-14 | 165759 |
VIZIMPRO | PFIZER CANADA ULC | Discontinued | 15MG | Updated Report | 2023-01-14 | 180950 |
VIZIMPRO | PFIZER CANADA ULC | Discontinued | 30MG | Updated Report | 2023-01-14 | 180953 |
VIZIMPRO | PFIZER CANADA ULC | Discontinued | 45MG | Updated Report | 2023-01-14 | 180956 |
ENBREL | IMMUNEX CORPORATION | Discontinued | 1ML 25MG | Updated Report | 2023-01-13 | 168157 |
URSO | APTALIS PHARMA CANADA ULC | Discontinued | 250MG | Updated Report | 2023-01-06 | 177861 |
1.6% SODIUM CHLORDIE PROCESSING SOLUTION | BAXTER CORPORATION | Discontinued | 1.6G | Updated Report | 2023-01-01 | 178273 |
HEPSERA | GILEAD SCIENCES CANADA INC | Discontinued | 10MG | Updated Report | 2022-12-27 | 171243 |
ZOLEDRONIC ACID FOR INJECTION | JUNO PHARMACEUTICALS CORP. | Discontinued | 4MG | Updated Report | 2022-12-24 | 179368 |
FOSRENOL | TAKEDA CANADA INC | To be discontinued | 250MG | New Report | 2022-12-20 | 178916 |
DEPO-PROVERA | PFIZER CANADA ULC | Discontinued | 150MG | New Report | 2022-12-20 | 178960 |
DEPO-PROVERA | PFIZER CANADA ULC | Discontinued | 150MG | New Report | 2022-12-20 | 178953 |
POTASSIUM CHLORIDE 20 MEQ IN 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE | ICU MEDICAL CANADA INC | Discontinued | 0.149G 0.3G 3.3G | Updated Report | 2022-12-15 | 148683 |